BackgroundCytokines play an important role in controlling the homeostasis of the immune system and infection with Human Immunodeficiency virus (HIV) leads to deregulated production of both pro- and anti-inflammatory cytokines. This study was designed to determine the effects of HIV and Highly Active Antiretroviral Therapy (HAART) on the levels of pro-and anti-inflammatory cytokines in HIV infected subjects.MethodA total of 50 HIV infected and 50 HIV seronegative control participants were recruited for the study. The HIV infected subjects were recruited before commencement of antiretroviral therapy and were followed up for 12 months. Blood samples were collected at 3 different points: before initiation of therapy, 6 months into therapy and 12 months into therapy. Serum cytokines were analyzed using ELISA method while CD4+ T cells and viral load counts were measured using standard laboratory methods.ResultThe results showed that pro-inflammatory cytokines: Tumour necrosis factor-alpha (TNF-α), Interleukin-6 (IL-6) and anti-inflammatory cytokines Interleukin-4 (IL-4), Interleukin-10 (IL-10) and Transforming growth factor-beta (TGF-β) were significantly elevated in HIV infected subjects before commencement of therapy compared to 6 months and 12 months into therapy (P < 0.01) and compared to control participants (P < 0.01). TNF-α, TGF-beta remained significantly elevated even after 12 months of therapy compared to control participants (P < 0.01), while IL-4, IL-6, and IL-10 showed no significant difference compared to control participants after 12 months of therapy (P > 0.05). INF-γ was significantly reduced before commencement of therapy and after 12 months of therapy compared to control participants (P < 0.05) respectively.ConclusionTNF-α and TGF-β remained significantly elevated even after 12 months of therapy, while IFN-γ remained significantly reduced after 12 months of therapy. Regulating these cytokines which were unresponsive to therapy could serve as a potential measure of therapy for HIV infected subjects. The positive effect of 12 months therapy on IL-4, IL-6 and IL-10 levels can be used to monitor disease prognosis during therapy especially in resource poor setting where regular viral load monitoring is unavailable.

No abstract

The present study was designed to assess the PCV and serum iron in HIV-malaria co-infected subjects in Nnewi, South Eastern Nigeria. 207 participants aged between 16-72 (44 ± 28) years were recruited and classified as follows based on standard screening and WHO criteria: (i) Asymptomatic HIV stage I subjects with or without malaria. (ii) Symptomatic HIV stage II subjects with or without malaria and not on (ART). (iii) HIV/AIDS subjects with or without malaria and on ART. (vi) HIV seronegative control subjects with or without malaria. Blood sample from these participants were analyzed for HIV seroreactivity, Plasmodium falciparum antigen, parasite density, serum iron concentrations and PCV using Standard Laboratory methods. The result showed that serum iron and PCV were significantly reduced amongst all the groups studied when compared with the control (p<0.01, <0.05, <0.01) respectively. No significant difference was observed in malaria parasite densities amongst all the groups studied. The present study shows that serum iron could possibly be one of the most significant predictors of anaemia in subjects presenting with HIV-malaria coinfection, other factors not withstanding. Effective antimalarial drugs in conjunction with antiretroviral therapy could go a long-way in reducing the incidence of anaemia associated with HIV/Malaria co-infection

The study was designed to evaluate some cellular immune index of HIV infected participants. For the study, 80 HIV infected participants were recruited for the study. They were aged 15 - 55 years. 45 of these participants were classified as Symptomatic HIV (Stage 11), while the remaining 35 were Asymptomatic HIV (Stage 1). Similarly, 40 HIV seronegative participants served as Control. Blood samples collected from the participants were used HIV screening and confirmation, CD4+ T cell count, absolute lymphocyte count and percent lymphocyte transformation. The CD4+T cell count and percent Lymphocyte Transformation count were significantly lowered in HIV infected participants compared with the HIV Seronegative participants (p&lt;0.05 in each case). Symptomatic HIV seropositive participants also presented with lowered CD4 and percent lymphocyte transformation, compared with the asymptomatic HIV participants (p&lt;0.05 in each case). The lowered CD4+T cell count suggests possible quantitative destruction of cellular immune cells (mainly Th1 cells). While the lowered percent blast formation in HIV infection indicates functional derangement of the cellular immune cells. Meanwhile no significant difference was observed in absolute lymphocyte count among the symptomatic, asymptomatic and control participants (p&gt; 0.05).

The study was designed to evaluate CD4 + T-cells count in subjects with HIV-malaria co-infection in Nnewi, South Eastern Nigeria and to assess the effects any changes in CD4 + counts has on the prevalence and or severity of both illness. Two hundred and eighty-five participants aged between 16 and 72 years were recruited for the study and grouped as symptomatic HIV subjects, asymptomatic HIV subjects, HIV/AIDS subjects on ART (Antiretroviral Therapy) and HIV-seronegative subjects. HIV and malaria parasite screening, CD4 + T-cell count and parasite density were determined using standard laboratory methods. The result showed that the prevalence of malaria infection was 75% in symptomatic HIV, 46.7% in asymptomatic HIV and 59.6% in HIV/AIDS subjects on ART respectively as opposed to 26.9% observed in the control (P<0.001). The CD4 + T-cell count was significantly lower in both symptomatic and asymptomatic HIV-malaria infected subjects when compared with the malaria-infected control subjects (238 ± 176, 312 ± 144, P<0.01) respectively. CD4 + T-cells count was also significantly lower in malaria-infected HIV/AIDS on ART when compared to the malaria-infected control subjects (315 ± 195, P<0.01). The study concludes that malaria prevalence is increased in subjects with HIV/malaria co-infection and is accompanied by a significant reduction in CD4 + T-cell counts, which might worsen the severity and prognosis in these subjects. Other public health implications are discussed.